Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TOS-358 |
Synonyms | |
Therapy Description |
TOS-358 inhibits PIK3CA, which potentially results in decreased tumor growth (Eur J Cancer 2022 Vol 174, Supp 1:S38). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TOS-358 | TOS 358|TOS358 | PIK3CA inhibitor 24 | TOS-358 inhibits PIK3CA, which potentially results in decreased tumor growth (Eur J Cancer 2022 Vol 174, Supp 1:S38). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA mutant | Advanced Solid Tumor | predicted - sensitive | TOS-358 | Preclinical - Pdx | Actionable | In a preclinical study, TOS-358 demonstrated efficacy in patient-derived xenograft (PDX) and cell line xenograft models harboring PIK3CA mutations (Cancer Res (2023) 83 (7_Supplement): 4946). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05683418 | Phase I | TOS-358 | A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors | Recruiting | USA | 0 |